NOVEL RADIOLABELED PEPTIDES FOR NON-INVASIVE BREAST CANCER IMAGING

用于非侵入性乳腺癌成像的新型放射性标记肽

• 批准号: 8167587
• 负责人: Yubin Miao
• 金额: $ 10.85万
• 依托单位: NEW MEXICO STATE UNIVERSITY LAS CRUCES
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-01 至 2011-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167587
• 关键词: Breast Cancer Cell; Cancer Etiology; Cessation of life; Computer Retrieval of Information on Scientific Projects Database; Deoxyglucose; Detection; Diagnostic; Early Diagnosis; Funding; Gonadotropin Hormone Releasing Hormone; Gonadotropin-Releasing Hormone Receptor; Grant; Image; Institution; Metastatic/Recurrent; Molecular Target; Patients; Peptides; Positron-Emission Tomography; Radiolabeled; Research; Research Design; Research Personnel; Resources; Second Primary Cancers; Sensitivity and Specificity; Series; Source; Specimen; Therapeutic Agents; United States National Institutes of Health; Woman; Xenograft procedure; cancer diagnosis; cancer imaging; design; imaging probe; improved; insight; malignant breast neoplasm; novel; radiotracer

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in women. Unfortunately, no curative treatment exists for metastatic breast cancer. Early diagnosis of breast cancer provides the patients the best opportunities for cures or prolonged survival. Current [18F]FDG (2-[18F]fluoro-2-deoxy-D-glucose) PET (positron emission tomography) imaging has limited use by relatively low sensitivity and specificity. Novel and more effective imaging probes are urgently needed to improve the detection accuracy of primary, metastatic and recurrent breast cancers. Our strategy to improve the detection accuracy for breast cancer focuses on developing novel radiolabeled gonadotropin-releasing hormone (GnRH) peptides to target the GnRH receptors. GnRH receptor is a distinct molecular target in this project for developing more effective breast cancer-specific imaging probes due to its over-expression on human breast cancer cells and specimens. We will synthesize and evaluate a series of novel radiolabeled GnRH peptides in human breast cancer cells and xenografts in this project. Our central hypothesis and research design are strongly supported by our positive preliminary results. Positive results from this project will firstly demonstrate the feasibility of using the radiolabeled GnRH peptides for breast cancer imaging and provide new insight into the design of novel and more effective diagnostic and therapeutic agents for breast cancer.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 乳腺癌是最常见的癌症，也是妇女癌症死亡的第二大原因。不幸的是，对于转移性乳腺癌不存在治愈性治疗。乳腺癌的早期诊断为患者提供了治愈或延长生存期的最佳机会。目前的[18 F]FDG（2-[18 F]氟-2-脱氧-D-葡萄糖）PET（正电子发射断层扫描）成像由于相对较低的灵敏度和特异性而限制了其使用。迫切需要新的和更有效的成像探针来提高原发性、转移性和复发性乳腺癌的检测准确性。 我们的策略，以提高乳腺癌的检测准确性，重点是开发新的放射性标记的促性腺激素释放激素（GnRH）肽靶向GnRH受体。由于GnRH受体在人乳腺癌细胞和标本中的过表达，因此GnRH受体是本项目开发更有效的乳腺癌特异性成像探针的独特分子靶标。本研究拟合成一系列新型的放射性标记GnRH肽，并在人乳腺癌细胞和异种移植瘤中进行评价。我们的中心假设和研究设计得到了我们积极的初步结果的有力支持。该项目的阳性结果将首次证明放射性标记的GnRH肽用于乳腺癌成像的可行性，并为设计新型和更有效的乳腺癌诊断和治疗药物提供新的见解。